231 related articles for article (PubMed ID: 31494007)
1. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
2. Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors.
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Bokemeyer C
Eur J Cancer; 2018 May; 94():16-25. PubMed ID: 29505967
[TBL] [Abstract][Full Text] [Related]
3. Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3).
Seidel C; Daugaard G; Nestler T; Tryakin A; Fedyanin M; Fankhauser C; Hermanns T; Aparicio J; Heinzelbecker J; Paffenholz P; Heidenreich A; De Giorgi U; Cathomas R; Lorch A; Fingerhut A; Gayer F; Bremmer F; Giannatempo P; Necchi A; Aurilio G; Casadei C; Tran B; Dieckmann KP; Brito M; Ruf C; Oing C; Bokemeyer C
Eur J Cancer; 2020 Jun; 132():127-135. PubMed ID: 32361383
[TBL] [Abstract][Full Text] [Related]
4. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
Gillessen S; Sauvé N; Collette L; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Beyer J;
J Clin Oncol; 2021 May; 39(14):1563-1574. PubMed ID: 33822655
[TBL] [Abstract][Full Text] [Related]
5. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
6. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
[TBL] [Abstract][Full Text] [Related]
7. Lens Culinaris Agglutinin-reactive Fraction of Alpha-fetoprotein as a Tumor Marker in a Patient With Nonseminomatous Germ Cell Tumor With Normal Alpha-fetoprotein Level.
Sugiyama H; Takeshita H; Tachibana K; Hiranuma S; Takagi D; Kagawa M; Yano A; Okada Y; Morozumi M; Kawakami S
Clin Genitourin Cancer; 2020 Jun; 18(3):e309-e311. PubMed ID: 31926880
[No Abstract] [Full Text] [Related]
8. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
[TBL] [Abstract][Full Text] [Related]
9. miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy.
Rosas Plaza X; van Agthoven T; Meijer C; van Vugt MATM; de Jong S; Gietema JA; Looijenga LHJ
Cells; 2019 Oct; 8(10):. PubMed ID: 31597402
[TBL] [Abstract][Full Text] [Related]
10. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.
Aparicio J; Sánchez-Muñoz A; Ochenduszko S; Gumà J; Fernández-Aramburo A; García Del Muro X; Quiroga V; Sastre J; Alonso-Gordoa T; Sagastibelza N; Maroto P; Gómez de Liaño A; Vázquez S; Diz P; Durán I; Domenech M; Pinto A; Hernández A; González-Billalabeitia E; Terrasa J
J Urol; 2019 Oct; 202(4):742-747. PubMed ID: 31163007
[TBL] [Abstract][Full Text] [Related]
11. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status.
Tryakin A; Fedyanin M; Bulanov A; Kashia S; Kurmukov I; Matveev V; Fainstein I; Gordeeva O; Zakharova T; Tjulandin S
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1817-1823. PubMed ID: 29974210
[TBL] [Abstract][Full Text] [Related]
12. Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation.
Raggi D; Mariani L; Giannatempo P; Lo Vullo S; Giardiello D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Calareso G; Magni M; Di Nicola M; Verzoni E; Grassi P; Procopio G; De Braud F; Pizzocaro G; Salvioni R; Necchi A
Urol Oncol; 2015 Jul; 33(7):332.e19-24. PubMed ID: 25985712
[TBL] [Abstract][Full Text] [Related]
13. Serum lactate dehydrogenase isoenzyme 1 and tumour volume are indicators of response to treatment and predictors of prognosis in metastatic testicular germ cell tumours.
von Eyben FE; Blaabjerg O; Madsen EL; Petersen PH; Smith-Sivertsen C; Gullberg B
Eur J Cancer; 1992; 28(2-3):410-5. PubMed ID: 1375486
[TBL] [Abstract][Full Text] [Related]
14. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
Mazumdar M; Bajorin DF; Bacik J; Higgins G; Motzer RJ; Bosl GJ
J Clin Oncol; 2001 May; 19(9):2534-41. PubMed ID: 11331333
[TBL] [Abstract][Full Text] [Related]
15. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
Gerl A; Lamerz R; Clemm C; Mann K; Hartenstein R; Wilmanns W
Clin Cancer Res; 1996 Sep; 2(9):1565-70. PubMed ID: 9816334
[TBL] [Abstract][Full Text] [Related]
16. Clinical Characteristics and Treatment Outcomes of Patients With Advanced Germ Cell Tumor Treated at a Tertiary Cancer Center in Brazil.
Vasconcellos VF; Bastos DA; Pereira AAL; Watarai GY; Pereira BR; de Godoy A; Almeida-Silva J; Muniz DQB; Guglielmetti GB; Nahas WC; Dzik C
J Glob Oncol; 2019 Feb; 5():1-8. PubMed ID: 30779600
[TBL] [Abstract][Full Text] [Related]
17. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.
Albany C; Adra N; Snavely AC; Cary C; Masterson TA; Foster RS; Kesler K; Ulbright TM; Cheng L; Chovanec M; Taza F; Ku K; Brames MJ; Hanna NH; Einhorn LH
Ann Oncol; 2018 Feb; 29(2):341-346. PubMed ID: 29140422
[TBL] [Abstract][Full Text] [Related]
18. Dose-dense chemotherapy for untreated poor-prognosis and relapsed germ-cell tumours: an 18-year experience with GAMEC chemotherapy.
Shamash J; Mee M; Sarker SJ; Wilson P; Ansell W; Greenwood M; Berney D; Alifrangis C
BJU Int; 2020 Jun; 125(6):843-852. PubMed ID: 31688976
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease.
Gerl A; Clemm C; Lamerz R; Mann K; Wilmanns W
Eur J Cancer; 1993; 29A(7):961-5. PubMed ID: 7684597
[TBL] [Abstract][Full Text] [Related]
20. Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling.
Kollmannsberger C; Nichols C; Meisner C; Mayer F; Kanz L; Bokemeyer C
Ann Oncol; 2000 Sep; 11(9):1115-20. PubMed ID: 11061604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]